<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365740</url>
  </required_header>
  <id_info>
    <org_study_id>248/13</org_study_id>
    <nct_id>NCT02365740</nct_id>
  </id_info>
  <brief_title>Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options</brief_title>
  <official_title>Postprandial Blood Glucose Control and Gastric Emptying in Patients With Type 1 Diabetes: Pathogenetic Factors, Clinical Relevance and Possible Therapeutic Options</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <brief_summary>
    <textblock>
      This study evaluates the prevalence of gastric emptying (GE) in type 1 diabetic patients
      (DM1) free of chronic complications in comparison with a group of healthy control subjects.
      The investigators will also assess the relationship between GE and glucose control (HbA1c,
      postprandial glucose variability), gut peptide hormones (GLP-1, GIP, and ghrelin), and
      gastrointestinal symptoms.

      In addition, in patients with delayed GE the investigators will investigate the effect of
      &quot;tailored&quot; pre-prandial insulin bolus administered by means of insulin pump in reducing
      postprandial glucose variability, evaluated through continuous glucose monitoring system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic patients with a delayed GE will be studied in 2 separate occasions in euglycemic
      condition and under CGM. On both occasions, they will have to take a standard meal poor of
      lipids (rice 60 g; yellow squash 200 g; extra virgin olive oil 7 g; adult veal lean cuts 90
      g; bananas 180 g; ordinary bread 75 g).

      On the first occasion pre-prandial insulin will be administered as single bolus calculated on
      the basis of carbohydrate counting and each patient's insulin/glycaemic load.

      On the second occasion the amount of pre-prandial insulin will be the same as the first one
      test but fractioned into a double-wave bolus. The &quot;tailored&quot; insulin bolus will be defined
      according to the individual pattern of GE, as follows:

        -  GE T1/2 121-180 min= 60% as bolus + 40% during following 2 h

        -  GE T1/2 &gt;180 min= 40% as bolus + 60% during following 4 h Glycemic variability will be
           assessed by the means of Continuous Glucose Monitoring System and the following indexes
           of glucose variability will be calculated: number of hypoglycemic events, number of
           hyperglycemic events, standard deviation of glycemia, glycemia variation coefficient,
           mean range of daily glycemia, interquartile range, M value, mean amplitude of glycemic
           excursions (MAGE), low blood glucose index (LBGI), high blood glucose index (HBGI).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gastric emptying measure</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gut hormones dosage</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Glucose Monitoring</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial glucose variability after single insulin bolus</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial glucose variability after double-wave insulin bolus</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>gastric emptying test gut hormones determination</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gastric emptying test</intervention_name>
    <description>gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gut hormones determination</intervention_name>
    <description>blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuous Glucose Monitoring</intervention_name>
    <description>7 days Continuous Glucose Monitoring</description>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin single bolus</intervention_name>
    <description>pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load</description>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin double-wave bolus</intervention_name>
    <description>pre-prandial insulin fractioned into a double-wave bolus</description>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DM1;

          -  Use of insulin pump;

          -  Disease duration ≥ 3 years.

        Exclusion Criteria:

          -  Presence of chronic complications of DM (including cardiovascular autonomic
             neuropathy);

          -  BMI ≥ 30 kg/m2;

          -  Presence of chronic diseases other than DM1;

          -  Diseases that interfere with GE;

          -  Medications that interfere with blood glucose homeostasis (except insulin) and GE.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of &quot;Medicina Clinica e Chirurgia&quot; of Federico II University</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brunella Capaldo, MD</last_name>
      <phone>0817462311</phone>
      <email>bcapaldo@unina.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberta Lupoli, MD</last_name>
      <phone>0817462427</phone>
      <email>sereroby@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Brunella Capaldo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta Lupoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lutgarda Bozzetto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Annuzzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>February 18, 2015</last_update_submitted>
  <last_update_submitted_qc>February 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Brunella Capaldo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Type 1 Diabetes mellitus</keyword>
  <keyword>Gastric Emptying</keyword>
  <keyword>Insulin Infusion Pump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

